Compare Fox Corp Class A (FOXA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Neurocrine Biosciences Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $25.36B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays a 0.91% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FOXA | NBIX | |
|---|---|---|
Market Cap | $25.36B | $14.36B |
Volume | 2,566,954 | 1,237,180 |
Sector | Media | Health |
52-Week High | $76.11 | $185.50 |
52-Week Low | $48.79 | $123.10 |
Typical Hold Time | 34 Days | 23 Days |
Enterprise Value | $28.72B | $14.37B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $62.68, down slightly by 0.03% on the day. The stock shows a bullish technical signal with strong earnings beats in recent quarters, including Q2 2026 EPS of $1.79 versus $1.44 expected. Revenue grew to $16.30 billion in 2025, with a net income margin of 13.88%. Key developments include the pending $22 billion acquisition of Roku, which is under DOJ review, and a dividend payment scheduled for September 2026.
The outlook is positive with a consensus price target of $72.00, implying 15% upside. Strengths include robust cash flow and analyst support, but risks involve regulatory scrutiny of the Roku deal and a projected decline in 2026 net income. The stock presents a value opportunity with a P/E of 16.55, though investors should monitor deal progression and earnings sustainability.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
